1
|
Castaño N, Cordts SC, Nadeau KC, Tsai M, Galli SJ, Tang SKY. Microfluidic methods for precision diagnostics in food allergy. BIOMICROFLUIDICS 2020; 14:021503. [PMID: 32266046 PMCID: PMC7127910 DOI: 10.1063/1.5144135] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Accepted: 03/12/2020] [Indexed: 05/29/2023]
Abstract
Food allergy has reached epidemic proportions and has become a significant source of healthcare burden. Oral food challenge, the gold standard for food allergy assessment, often is not performed because it places the patient at risk of developing anaphylaxis. However, conventional alternative food allergy tests lack a sufficient predictive value. Therefore, there is a critical need for better diagnostic tests that are both accurate and safe. Microfluidic methods have the potential of helping one to address such needs and to personalize the diagnostics. This article first reviews conventional diagnostic approaches used in food allergy. Second, it reviews recent efforts to develop novel biomarkers and in vitro diagnostics. Third, it summarizes the microfluidic methods developed thus far for food allergy diagnosis. The article concludes with a discussion of future opportunities for using microfluidic methods for achieving precision diagnostics in food allergy, including multiplexing the detection of multiple biomarkers, sampling of tissue-resident cytokines and immune cells, and multi-organ-on-a-chip technology.
Collapse
Affiliation(s)
- Nicolas Castaño
- Department of Mechanical Engineering, Stanford University, Stanford, California 94305, USA
| | - Seth C. Cordts
- Department of Mechanical Engineering, Stanford University, Stanford, California 94305, USA
| | - Kari C. Nadeau
- Department of Pediatrics—Allergy and Clinical Immunology, Stanford University, Stanford, California 94305, USA
| | - Mindy Tsai
- Department of Pathology, Stanford University, Stanford, California 94305, USA
| | | | - Sindy K. Y. Tang
- Department of Mechanical Engineering, Stanford University, Stanford, California 94305, USA
| |
Collapse
|
3
|
Wilsgaard T, Mathiesen EB, Patwardhan A, Rowe MW, Schirmer H, Løchen ML, Sudduth-Klinger J, Hamren S, Bønaa KH, Njølstad I. Clinically significant novel biomarkers for prediction of first ever myocardial infarction: the Tromsø Study. ACTA ACUST UNITED AC 2015; 8:363-71. [PMID: 25613532 DOI: 10.1161/circgenetics.113.000630] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2013] [Accepted: 01/08/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Identification of individuals with high risk for first-ever myocardial infarction (MI) can be improved. The objectives of the study were to survey multiple protein biomarkers for association with the 10-year risk of incident MI and identify a clinically significant risk model that adds information to current common risk models. METHODS AND RESULTS We used an immunoassay platform that uses a sensitive, sample-efficient molecular counting technology to measure 51 proteins in samples from the fourth survey (1994) in the Tromsø Study, a longitudinal study of men and women in Tromsø, Norway. A case control design was used with 419 first-ever MI cases (169 females/250 males) and 398 controls (244 females/154 males). Of the proteins measured, 17 were predictors of MI when considered individually after adjustment for traditional risk factors either in men, women, or both. The 6 biomarkers adjusted for traditional risk factors that were selected in a multivariable model (odds ratios [OR] per standard deviation) using a stepwise procedure were apolipoprotein B/apolipoprotein A1 ratio (1.40), kallikrein (0.73), lipoprotein a (1.29), matrix metalloproteinase 9 (1.30), the interaction term IP-10/CXCL10×women (0.69), and the interaction term thrombospondin 4×men (1.38). The composite risk of these biomarkers added significantly to the traditional risk factor model with a net reclassification improvement of 14% (P=0.0002), whereas the receiver operating characteristic area increased from 0.757 to 0.791, P=0.0004. CONCLUSIONS Novel protein biomarker models improve identification of 10-year MI risk above and beyond traditional risk factors with 14% better allocation to either high or low risk group.
Collapse
Affiliation(s)
- Tom Wilsgaard
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.).
| | - Ellisiv Bøgeberg Mathiesen
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| | - Anil Patwardhan
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| | - Michael W Rowe
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| | - Henrik Schirmer
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| | - Maja-Lisa Løchen
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| | - Julie Sudduth-Klinger
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| | - Sarah Hamren
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| | - Kaare Harald Bønaa
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| | - Inger Njølstad
- From the Departments of Community Medicine (T.W., M.-L.L., K.H.B., I.N.) and Clinical Medicine (E.B.M. H.S.), UiT The Arctic University of Norway, Norway; Division of Cardiothoracic and Respiratory Medicine, University Hospital of North Norway, Tromsø, Norway (H.S.); Tethys Bioscience, Emeryville, CA (A.P., M.W.R., J.S.-K.); Life Science Department, Singulex, Inc., Alameda, CA (S.H.); and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway (K.H.B.)
| |
Collapse
|
6
|
Tasoglu S, Gurkan UA, Wang S, Demirci U. Manipulating biological agents and cells in micro-scale volumes for applications in medicine. Chem Soc Rev 2013; 42:5788-808. [PMID: 23575660 PMCID: PMC3865707 DOI: 10.1039/c3cs60042d] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Recent technological advances provide new tools to manipulate cells and biological agents in micro/nano-liter volumes. With precise control over small volumes, the cell microenvironment and other biological agents can be bioengineered; interactions between cells and external stimuli can be monitored; and the fundamental mechanisms such as cancer metastasis and stem cell differentiation can be elucidated. Technological advances based on the principles of electrical, magnetic, chemical, optical, acoustic, and mechanical forces lead to novel applications in point-of-care diagnostics, regenerative medicine, in vitro drug testing, cryopreservation, and cell isolation/purification. In this review, we first focus on the underlying mechanisms of emerging examples for cell manipulation in small volumes targeting applications such as tissue engineering. Then, we illustrate how these mechanisms impact the aforementioned biomedical applications, discuss the associated challenges, and provide perspectives for further development.
Collapse
Affiliation(s)
- Savas Tasoglu
- Bio-Acoustic-MEMS in Medicine (BAMM) Laboratory, Division of Biomedical Engineering and Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Umut Atakan Gurkan
- Bio-Acoustic-MEMS in Medicine (BAMM) Laboratory, Division of Biomedical Engineering and Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - ShuQi Wang
- Bio-Acoustic-MEMS in Medicine (BAMM) Laboratory, Division of Biomedical Engineering and Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Utkan Demirci
- Bio-Acoustic-MEMS in Medicine (BAMM) Laboratory, Division of Biomedical Engineering and Division of Infectious Diseases, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- Harvard-MIT Health Sciences and Technology, Cambridge, MA, USA
| |
Collapse
|
7
|
Gurkan UA, Tasoglu S, Akkaynak D, Avci O, Unluisler S, Canikyan S, MacCallum N, Demirci U. Smart interface materials integrated with microfluidics for on-demand local capture and release of cells. Adv Healthc Mater 2012; 1:661-8. [PMID: 23184803 PMCID: PMC3774603 DOI: 10.1002/adhm.201200009] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2012] [Revised: 01/26/2012] [Indexed: 01/10/2023]
Abstract
Stimuli responsive, smart interface materials are integrated with microfluidic technologies creating new functions for a broad range of biological and clinical applications by controlling the material and cell interactions. Local capture and on-demand local release of cells are demonstrated with spatial and temporal control in a microfluidic system.
Collapse
Affiliation(s)
- Umut Atakan Gurkan
- Postdoctoral Research Fellow in Medicine, Harvard Medical School, Brigham and Women’s Hospital, Harvard-MIT Health Sciences & Technology, 65 Landsdowne St. PRB 252, Cambridge, MA 02139, USA
| | - Savas Tasoglu
- Postdoctoral Research Fellow in Medicine, Harvard Medical School, Brigham and Women’s Hospital, Harvard-MIT Health Sciences & Technology, 65 Landsdowne St. PRB 252, Cambridge, MA 02139, USA
| | - Derya Akkaynak
- Massachusetts Institute of Technology (MIT) Department of Mechanical Engineering, Woods Hole Oceanographic Institution (WHOI) Joint Program in Oceanography, Applied Ocean Science and Engineering, Cambridge, MA, USA
| | - Oguzhan Avci
- Harvard Medical School, Brigham and Women’s Hospital, 65 Landsdowne St. PRB 252, Cambridge, MA 02139, USA
| | - Sebnem Unluisler
- Harvard Medical School, Brigham and Women’s Hospital, 65 Landsdowne St. PRB 252, Cambridge, MA 02139, USA
| | - Serli Canikyan
- Harvard Medical School, Brigham and Women’s Hospital, 65 Landsdowne St. PRB 252, Cambridge, MA 02139, USA
| | - Noah MacCallum
- Harvard Medical School, Brigham and Women’s Hospital, 65 Landsdowne St. PRB 252, Cambridge, MA 02139, USA
| | - Utkan Demirci
- Assistant Professor, Harvard Medical School, Brigham and Women’s Hospital, Harvard-MIT Health Sciences & Technology, 65 Landsdowne St. PRB 252, Cambridge, MA 02139, USA
| |
Collapse
|